1880 related articles for article (PubMed ID: 25218350)
21. Inhibition of the Wnt/β-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma.
Lin HH; Feng WC; Lu LC; Shao YY; Hsu CH; Cheng AL
Cancer Lett; 2016 Oct; 381(1):58-66. PubMed ID: 27431312
[TBL] [Abstract][Full Text] [Related]
22. Downregulating hypoxia-inducible factor-2α improves the efficacy of doxorubicin in the treatment of hepatocellular carcinoma.
He C; Sun XP; Qiao H; Jiang X; Wang D; Jin X; Dong X; Wang J; Jiang H; Sun X
Cancer Sci; 2012 Mar; 103(3):528-34. PubMed ID: 22145922
[TBL] [Abstract][Full Text] [Related]
23. HIF-1α-induced RIT1 promotes liver cancer growth and metastasis and its deficiency increases sensitivity to sorafenib.
Song Z; Liu T; Chen J; Ge C; Zhao F; Zhu M; Chen T; Cui Y; Tian H; Yao M; Li J; Li H
Cancer Lett; 2019 Sep; 460():96-107. PubMed ID: 31247273
[TBL] [Abstract][Full Text] [Related]
24. 2-methoxyestradiol inhibits hypoxia-inducible factor 1alpha, tumor growth, and angiogenesis and augments paclitaxel efficacy in head and neck squamous cell carcinoma.
Ricker JL; Chen Z; Yang XP; Pribluda VS; Swartz GM; Van Waes C
Clin Cancer Res; 2004 Dec; 10(24):8665-73. PubMed ID: 15623651
[TBL] [Abstract][Full Text] [Related]
25. Hypoxia inducible factor 1α and hypoxia inducible factor 2α play distinct and functionally overlapping roles in oral squamous cell carcinoma.
Zhu GQ; Tang YL; Li L; Zheng M; Jiang J; Li XY; Chen SX; Liang XH
Clin Cancer Res; 2010 Oct; 16(19):4732-41. PubMed ID: 20807755
[TBL] [Abstract][Full Text] [Related]
26. Synergistic anti-hepatoma effect of bufalin combined with sorafenib via mediating the tumor vascular microenvironment by targeting mTOR/VEGF signaling.
Wang H; Zhang C; Chi H; Meng Z
Int J Oncol; 2018 Jun; 52(6):2051-2060. PubMed ID: 29620259
[TBL] [Abstract][Full Text] [Related]
27. The role of hypoxia-inducible factor-1α and -2α in androgen insensitive prostate cancer cells.
Jeong CW; Yoon CY; Jeong SJ; Hong SK; Byun SS; Kwak C; Lee SE
Urol Oncol; 2013 Nov; 31(8):1448-56. PubMed ID: 22537539
[TBL] [Abstract][Full Text] [Related]
28. GYY4137, a hydrogen sulfide (H₂S) donor, shows potent anti-hepatocellular carcinoma activity through blocking the STAT3 pathway.
Lu S; Gao Y; Huang X; Wang X
Int J Oncol; 2014 Apr; 44(4):1259-67. PubMed ID: 24535538
[TBL] [Abstract][Full Text] [Related]
29. Cyclin E1 Inhibition can Overcome Sorafenib Resistance in Hepatocellular Carcinoma Cells Through Mcl-1 Suppression.
Hsu C; Lin LI; Cheng YC; Feng ZR; Shao YY; Cheng AL; Ou DL
Clin Cancer Res; 2016 May; 22(10):2555-64. PubMed ID: 26603262
[TBL] [Abstract][Full Text] [Related]
30. Simvastatin re-sensitizes hepatocellular carcinoma cells to sorafenib by inhibiting HIF-1α/PPAR-γ/PKM2-mediated glycolysis.
Feng J; Dai W; Mao Y; Wu L; Li J; Chen K; Yu Q; Kong R; Li S; Zhang J; Ji J; Wu J; Mo W; Xu X; Guo C
J Exp Clin Cancer Res; 2020 Jan; 39(1):24. PubMed ID: 32000827
[TBL] [Abstract][Full Text] [Related]
31. Combining celecoxib with sorafenib synergistically inhibits hepatocellular carcinoma cells in vitro.
Morisaki T; Umebayashi M; Kiyota A; Koya N; Tanaka H; Onishi H; Katano M
Anticancer Res; 2013 Apr; 33(4):1387-95. PubMed ID: 23564777
[TBL] [Abstract][Full Text] [Related]
32. Modulating the hypoxia-inducible factor signaling pathway as a therapeutic modality to regulate retinal angiogenesis.
DeNiro M; Alsmadi O; Al-Mohanna F
Exp Eye Res; 2009 Nov; 89(5):700-17. PubMed ID: 19580810
[TBL] [Abstract][Full Text] [Related]
33. Treatment of hepatocellular carcinoma combining sorafenib and transarterial locoregional therapy: state of the science.
Weintraub JL; Salem R
J Vasc Interv Radiol; 2013 Aug; 24(8):1123-34. PubMed ID: 23562168
[TBL] [Abstract][Full Text] [Related]
34. Role of cyclophilin B in tumorigenesis and cisplatin resistance in hepatocellular carcinoma in humans.
Kim Y; Jang M; Lim S; Won H; Yoon KS; Park JH; Kim HJ; Kim BH; Park WS; Ha J; Kim SS
Hepatology; 2011 Nov; 54(5):1661-78. PubMed ID: 21748762
[TBL] [Abstract][Full Text] [Related]
35. Sorafenib suppresses the rapid progress of hepatocellular carcinoma after insufficient radiofrequency ablation therapy: an experiment in vivo.
Xu M; Xie XH; Xie XY; Xu ZF; Liu GJ; Zheng YL; Huang GL; Wang W; Zheng SG; Lü MD
Acta Radiol; 2013 Mar; 54(2):199-204. PubMed ID: 23171528
[TBL] [Abstract][Full Text] [Related]
36. Magnolol suppresses hypoxia-induced angiogenesis via inhibition of HIF-1α/VEGF signaling pathway in human bladder cancer cells.
Chen MC; Lee CF; Huang WH; Chou TC
Biochem Pharmacol; 2013 May; 85(9):1278-87. PubMed ID: 23416116
[TBL] [Abstract][Full Text] [Related]
37. Activation of PI3 kinase/Akt/HIF-1α pathway contributes to hypoxia-induced epithelial-mesenchymal transition and chemoresistance in hepatocellular carcinoma.
Jiao M; Nan KJ
Int J Oncol; 2012 Feb; 40(2):461-8. PubMed ID: 21922131
[TBL] [Abstract][Full Text] [Related]
38. Antisense hypoxia-inducible factor 1alpha gene therapy enhances the therapeutic efficacy of doxorubicin to combat hepatocellular carcinoma.
Liu F; Wang P; Jiang X; Tan G; Qiao H; Jiang H; Krissansen GW; Sun X
Cancer Sci; 2008 Oct; 99(10):2055-61. PubMed ID: 19016766
[TBL] [Abstract][Full Text] [Related]
39. Effects of 2-methoxyestradiol on apoptosis and HIF-1α and HIF-2α expression in lung cancer cells under normoxia and hypoxia.
Aquino-Gálvez A; González-Ávila G; Delgado-Tello J; Castillejos-López M; Mendoza-Milla C; Zúñiga J; Checa M; Maldonado-Martínez HA; Trinidad-López A; Cisneros J; Torres-Espíndola LM; Hernández-Jiménez C; Sommer B; Cabello-Gutiérrez C; Gutiérrez-González LH
Oncol Rep; 2016 Jan; 35(1):577-83. PubMed ID: 26548300
[TBL] [Abstract][Full Text] [Related]
40. Opposite functions of HIF-α isoforms in VEGF induction by TGF-β1 under non-hypoxic conditions.
Chae KS; Kang MJ; Lee JH; Ryu BK; Lee MG; Her NG; Ha TK; Han J; Kim YK; Chi SG
Oncogene; 2011 Mar; 30(10):1213-28. PubMed ID: 21057546
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
